China
Africa
Explore chapters and articles related to this topic
Disorders of Keratinization and Other Genodermatoses
Published in Ayşe Serap Karadağ, Lawrence Charles Parish, Jordan V. Wang, Roxburgh's Common Skin Diseases, 2022
Roselyn Stanger, Nanette Silverberg
Clinical presentation: The most common presentation are follicular papules of the cheeks, upper arms, and thighs, beginning in the toddler years and showing facial improvement in teen years. Background erythema and associated pruritus is often noted. Severe disease can cause loss of the eyebrows, termed ulerythema ophyrogenes, which can be seen in syndromes, such as cardiofaciocutaneous syndrome.
Cicatricial alopecias: Pathogenesis, classification, clinical features, diagnosis, and management
Published in Jerry Shapiro, Nina Otberg, Hair Loss and Restoration, 2015
Keratosis follicularis spinulosa decalvans (KFSD) together with keratosis atrophicans faciei (also called ulerythema oophrygenes or keratosis pilaris rubra atrophicans faciei) and atrophodermia vermiculata belong to a heterogeneous group of congenital follicular keratinizing disorders. KFSD is X-linked and usually develops during adolescence and mostly presents with scarring alopecic patches, follicular hyperkeratosis, and rarely pustules [4]. Eyebrow and eyelash involvement can also be present [82–84].
Treatment of keratosis pilaris and its variants: a systematic review
Published in Journal of Dermatological Treatment, 2022
Jalal Maghfour, Sophia Ly, Wasim Haidari, Sarah L. Taylor, Steven R. Feldman
A comprehensive systematic review was performed using PubMed/MEDLINE, Embase, Cochrane review and Web of Science databases. The search terms included: ‘Keratosis pilaris’ OR ‘Keratosis pilaris alba’ OR ‘Keratosis pilaris rubra’ OR ‘Keratosis pilaris atrophicans’ OR ‘Keratosis follicularis spinulosa decalvans’ OR ‘Atrophoderma vermiculata’ OR ‘KP atrophicans facei OR Ulerythema ophryogenes’ OR ‘Erythromelanosis follicularis faciei et colli’ AND ‘treatment’. Studies were searched from inception to present time. Full-text articles reporting treatment for KP and its variants were included. There were no geographical or age restrictions. The following study types were excluded: 1) studies with patients on systemic agents known to induce KP (i.e. epidermal-growth factor receptor inhibitors; 2) studies that were unable to be translated in English; and 3) studies with no outcome measures.